This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
Patients must to be 12 years old (inclusive) at the time of signing the informed consent.
Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
You may not be if
Patients currently participating in any other clinical trial.
Known history of allergy or reaction to any component of the study treatment formulation.
Malignancy of any kind.
Patients with prior or ongoing treatment with benralizumab.
Clareo Health | This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
